Eurofins drops as organic growth disappoints
BUZZ-Eurofins drops as organic growth disappoints July 23 - ** Shares in Eurofins Scientific EUFI.PA fall 6% after the laboratory testing group reported weaker-than-expected first-half organic growth
** Jeffries says the company's H1 organic growth of 2.7% is "well below expectations" and "disappoints again," with second-quarter organic growth of about 3% missing consensus of 4.2%, impacted by weak biopharma growth
** The broker adds that Eurofins' full-year outlook is unchanged, but organic growth targets now look more conditional, requiring acceleration in the second-half
** TP ICAP Midcap says biopharma remains the key factor in Eurofins' ability to return to its medium-term organic growth ambition
** Shares are on track for the worst day since April 22, when they closed 9.7% lower after "disappointing Q1"
(Reporting by Aleksandra Kret in Gdansk)
Recent news on Eurofins Scientific SE
See all newsEurope Research Roundup: Avio, Genmab, Veolia
Europe Research Roundup: Avio, Genmab, Kerry Group
Brief: Eurofins 9M Revenues €5.61 Bln
European life sciences stocks rise on strong sector momentum
Brief: Eurofins Completes The Acquisition Of Element Materials Technology’S Life Sciences Testing Services Business